关于我们
Research increasingly demonstrates that an over-active immune system and the resulting spikes in inflammation, are actually worse for healing. When injury first occurs, tissue specific macrophages initiate the inflammatory cascade by releasing cytokines into the blood stream. These inflammatory markers recruit additional macrophages to the site of injury. In chronic or deleterious forms of inflammation, these recruited macrophages arrive at the scene in M1 or “destructive” phenotype, long after necrotic tissue or pathogens are removed; causing unnecessary damage and perpetuating the cycle of inflammation. Our NF-kB blocker leverages a nano-particle delivery system to target and re-polarize recruited macrophages to the M2 or “restorative” phenotype, moderating inflammation and improving remodeling.
- 网站
-
https://bluegrass-pharma.com/
Bluegrass Pharmaceuticals的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 类型
- 私人持股
- 创立
- 2024